Mildly active disease, defined by clinical symptoms using the Harvey Bradshaw Index (HBI) score between 5 and 7 (the HBI is a continuous score ranging from 0-16 where \<4 is considered remission)
BMI ≥ 27 kg/m2
Patients will be on stable doses of medical therapy (anti-tumor necrosis factor (TNF) alpha blockers)
You may not be if
Patients under 18 years of age
Patients with ulcerative colitis
Patients with infectious colitis
BMI\<27 kg/m2
Patients with type 1 or type 2 diabetes
Contraindications to a GIP/GLP-1 RA, including patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2
Patients already on GIP/GLP-1 RA therapy
Patients with the following chronic symptoms: severe constipation, nausea, and/or vomiting
Patients with the following medical history: small bowel obstruction in the last year, intestinal stricture, known or suspected diagnosis of gastroparesis
Adults unable to consent
Pregnant patients (will be confirmed via a pregnancy test)
Prisoners
Clareo Health | Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
